Humira® Biosimilars: Reaching the Market’s Cost-Savings Potential

In 2023, a wave of biosimilars for Humira® (adalimumab) are set to hit the market. The next 18 months will be consequential in determining the future success of the biosimilars market in the U.S. Download the below one-pager to learn more.